G1 Therapeutics Gets $12.5M Series A To Advance Chemo-Protectant Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Based on research from the University of North Carolina and seeded by Hatteras Venture Partners, the start-up is developing cyclin-dependent kinase (CDK) 4/6 inhibitors for use in protecting the bone marrow of cancer patients receiving chemotherapy. The funding should bring the biotech through IND filing and into Phase I work.
You may also be interested in...
AstraZeneca Commits $100 Million To MedImmune Ventures
The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.